Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

34) Interest income 3 212 48 1,001 Interest expense (52) (183) (240) (640) Other income (expense), net -- (12) 10 26 --- --- --- --- Net loss $(6,756) $(6,313) $(16,789) $(21,247) ======= ======= ======== ======== Basic and diluted net loss per share $(0.38) $(0.36) $(0.95) $(1.21) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 17,617,209 17,538,886 17,588,832 17,508,094 ========== ========== ========== ========== Non-cash stock-based compensation expense included in operating expenses: (1) Research and development $148 $183 $596 $597 (2) General and administrative 576 190 1,025 570 ---- ---- ------ ------ $724 $373 $1,621 $1,167 ==== ==== ====== ======
                           NEUROGESX, INC.
               Condensed Consolidated Balance Sheets
                           (in thousands)

                                               September 30,   December 31,
                                                   2009            2008
                                               -------------   ------------
                                                 (unaudited)        (1)
                                                 -----------        ---
                           Assets
     Current assets:
       Cash and cash equivalents                     $48,468        $10,435
       
'/>"/>
SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 6, 2015 ... von der Assistance Publique - Hôpitaux de ... ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie für ... wurden. Verglichen werden Patienten mit fortgeschrittenem hepatozellulärem ... oder Sorafenib behandelt wurden. Die Ergebnisse werden ...
(Date:3/5/2015)... LifeCell Dx and its founder, Dr. Lani ... Advanced Semen Analysis before they do anything else about ... risk factors for struggling couples.Too often, the traditional path ... the infertility. Infertility is fairly equally divided between the ... least complicated and inexpensive analysis that provides far more ...
(Date:3/5/2015)... 2015 North Carolina-based life sciences ... Professor of Medicine, Mayo Clinic College of Medicine, ... Directors. , Entegrion’s Executive Chairman John ... have Dr. Noel, a distinguished physician and researcher ... Entegrion’s Board. His expertise in hematology and military ...
(Date:3/5/2015)... 2015  In response to the incorrect assertions by ... on February 12, 2015. Impeto Medical SAS ... health and their SUDOSCAN® devices have been proven to ... prefers to have the courts decide this dispute rather ... 40 articles written by Key Opinion Leaders, published by ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2
... , Overview ... study of protein biomarkers increases in importance, extensive lists of candidate ... proteomics experiments. Even larger numbers of candidate genomic markers exist from ... genomic information. , While these ...
... Reverse transcription-polymerase chain reaction ... abundant double-stranded DNA product (1,2,3). RT-PCR is a powerful ... RNA splice variants. RT-PCR is generally carried out as either ... tube and RT and PCR are conducted sequentially in this ...
... Researchers and forensic agencies that test samples or screen post mortem ... from a number of limitations: , They lack ... available for novel sample matrices such as saliva as they are for urine or serum ... due to the high volume of reagents used. , ...
Cached Biology Technology:Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 2Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 3Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 4Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma 5Simple Approaches for Optimization of RT-PCR 2Simple Approaches for Optimization of RT-PCR 3Simple Approaches for Optimization of RT-PCR 4Simple Approaches for Optimization of RT-PCR 5Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 2Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 3Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method 4
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... 28, 2015 New Market Research ... Segment Forecasts To 2020 has Been Added to GrandViewReseach.com ... is expected to reach USD 5.10 billion by 2020, ... Inc. IR cameras help identify the site of tissue ... witness surging demand in medical imaging applications. They have ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... comprehensive reconstruction of an extreme warm period shows the ... dioxide (CO 2 ) levels as well as the ... regions, and greenhouse gases on Earth,s temperature. ... future climate and improved understanding of today,s warming. Past ...
... open any biology textbook and you,re bound to see ... cell, with its internal scaffolding, the cytoskeleton, and ... question remains, which came first: the shape, or the ... PhD, Assistant Professor of Cell and Developmental Biology at ...
... A tale of two sisters has helped researchers solve a ... an inherited form of the lung disease Pulmonary Alveolar Proteinosis ... Journal of Experimental Medicine , a research team led by ... of an inhaled therapy to overcome a chain of molecular ...
Cached Biology News:Getting warmer? Prehistoric climate can help forecast future changes 2Penn scientists discover cells reorganize shape to fit the situation 2Penn scientists discover cells reorganize shape to fit the situation 3Inherited genetic cause, possible treatment found for complex lung disorder 2Inherited genetic cause, possible treatment found for complex lung disorder 3
... Y2 Receptor antiserum This NPY Y2 ... level and is currently being characerized in brain. ... and mouse and appears to work better on ... rat. For full characterizarion in dorsal root ganglion ...
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Synucleins are small, soluble proteins expressed ... tumors. The family includes three known proteins: ... The alpha and beta synuclein proteins are ... are seen mainly in presynaptic terminals. ...
... antibody is specific for human cardiac troponin subunit ... Ca-binding signals responsible for contraction of cardiac muscle. ... complex in human cells. It also cross-reacts with ... Antigen: Highly purified human cardiac ...
Biology Products: